Neuren Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NEU.AX research report →
Price Chart
About the company
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins.
- CEO
- Jonathan Charles Pilcher
- IPO
- 2005
- Employees
- 9
- HQ
- Hawthorn East, VIC, AU
Get TickerSpark's AI analysis on NEU.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.85B
- P/E
- 93.58
- Fwd P/E
- 64.09
- PEG
- -1.19
- P/S
- 44.05
- P/B
- 8.40
- EV/EBITDA
- 128.96
- Div Yield
- 0.00%
- Gross Margin
- 76.93%
- Op Margin
- 11.03%
- Net Margin
- 47.09%
- ROE
- 9.20%
- ROIC
- 1.65%
Latest fiscal year · YoY change
- Revenue
- $64.63M-69.7%
- Gross Profit
- $64.61M-69.7%
- Op Income
- $22.02M
- Net Income
- $30.44M-78.6%
- EPS
- $0.24-78.4%
- OCF Growth
- +1212.9%
- FCF Growth
- +1211.6%
- 52W High
- $23.76
- 52W Low
- $11.00
- 50D MA
- $17.72
- 200D MA
- $15.76
- Beta
- 1.59
- RSI (14)
- 66
- Avg Volume
- 551.23K
No earnings-call transcripts are available for NEU.AX yet.
- Free Float
- 86.6%
- Shares Outstanding
- 126.77M
- Float Shares
- 109.74M
of shares held by institutions
1 13F filers
Held by 181 ETFs
Biggest fund positions in NEU.AX by dollar value.
Our NEU.AX coverage
Recent articles, reports, and earnings notes.
No research on NEU.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NEU.AX report →